Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 9/20 | 0.59 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4381527 | 0.80 | EDNRA (0.53) | EDNRATAS1R3TAS1R1KMT2ACYP3A4 | |
| SCHEMBL2862126 | 0.80 | EDNRA (0.52) | EDNRATAS1R3TAS1R1KMT2ACYP3A4 | |
| SCHEMBL22404286 | 0.80 | EDNRA (0.56) | EDNRATAS1R3TAS1R1KMT2ACYP3A4 | |
| SCHEMBL12825470 | 0.79 | EDNRA (0.56) | EDNRATAS1R3TAS1R1KMT2AKDM4E | |
| SCHEMBL1746047 | 0.79 | PTGS2 (0.56) | EDNRATAS1R3TAS1R1KMT2AALDH1A1 | |
| SCHEMBL805660 | 0.79 | EDNRA (0.55) | EDNRATAS1R3TAS1R1KMT2ACYP3A4 | |
| SCHEMBL10204938 | 0.77 | EDNRA (0.54) | EDNRATAS1R3TAS1R1KMT2ACYP3A4 | |
| SCHEMBL14032401 | 0.77 | EDNRA (0.54) | EDNRATAS1R3TAS1R1KMT2ACYP3A4 | |
| SCHEMBL4996294 | 0.77 | EDNRA (0.54) | EDNRATAS1R3TAS1R1KMT2ACYP3A4 | |
| SCHEMBL805662 | 0.77 | EDNRA (0.54) | EDNRATAS1R3TAS1R1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538241-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070155813-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1704856-A1 | HSP90 FAMILY PROTEIN INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155813-A1 | Hsp90 family protein inhibitors | HSP90AB1, HEATR1, HSP90AB2P | EDNRA 2365/4885TAS1R3 1883/4885TAS1R1 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.